2nd illustrations and photographs
RayzeBio (RYZB) has up to date terms for a proposed $224M preliminary public providing.
The radiopharmaceuticals developer stated in an SEC submitting that it was keen on providing 13.2M shares priced between $16 and $18, which might increase round $224M if priced on the midpoint. Underwriters would be granted a 30-day choice to purchase as much as 2.2M extra shares to cowl over-allotments.
An present shareholder additionally plans to supply an extra 1.2M shares. RayzeBio wouldn’t see any proceeds from that sale.
RayzeBio hopes to listing its shares on Nasdaq below the image RYZB. JP Morgan, Jefferies, Evercore ISI and Truist Securities are serving as joint bookrunners.
The firm first filed for the IPO in August.
